Learn more →
Back to Expert Scholars
Translational Medicine / 转化医学Breast Cancer Advanced 2026

Young-Hyuck Im

林荣赫

MD, PhD

🏢Samsung Medical Center, Sungkyunkwan University School of Medicine(三星医疗中心,成均馆大学医学院)🌐South Korea

Professor; Director, Division of Hematology-Oncology教授;血液肿瘤科主任

48
h-index
2
Key Papers
3
Awards
2
Key Contributions

👥Biography 个人简介

Young-Hyuck Im, MD, PhD is a Professor and Division Director at Samsung Medical Center, one of Asia's leading breast cancer clinical research centers. He is a principal investigator for major global breast cancer trials including DESTINY-Breast series, CDK4/6 inhibitor studies, and pan-Asian research on HER2-directed therapy, contributing critical data on outcomes in Asian patient populations.

Share:

🧪Research Fields 研究领域

HER2-Positive Metastatic Breast CancerHER2阳性转移性乳腺癌
Trastuzumab Deruxtecan曲妥珠单抗德鲁替康
CDK4/6 InhibitorsCDK4/6抑制剂
HR-Positive Breast Cancer激素受体阳性乳腺癌
Asian Breast Cancer Epidemiology亚洲乳腺癌流行病学
Breast Cancer Clinical Trials Asia-Pacific亚太地区乳腺癌临床试验

🎓Key Contributions 主要贡献

HER2-Directed Therapy in Asian Populations

Led Korean and pan-Asian sub-studies of DESTINY-Breast trials evaluating T-DXd in HER2-positive and HER2-low MBC, providing key efficacy and safety data supporting therapy use in Asian patients who may differ in tumor biology and tolerability.

CDK4/6 Inhibitors in HR+ Breast Cancer

Conducted pivotal Asian-region studies of palbociclib, ribociclib, and abemaciclib in HR+/HER2- metastatic breast cancer, generating population-specific data that informed treatment guidelines across East Asia.

Representative Works 代表性著作

[1]

Trastuzumab Deruxtecan versus Trastuzumab Emtansine for HER2-Positive Metastatic Breast Cancer: Asia-Pacific Subgroup Analysis (DESTINY-Breast03)

ESMO Open (2023)

Asian-subgroup analysis demonstrating consistent T-DXd superiority over T-DM1 in HER2+ MBC in Korean and Asian patients, with important ILD safety characterization.

[2]

Palbociclib plus Letrozole as First-Line Therapy in East Asian Patients with ER+/HER2- Advanced Breast Cancer: PALOMA-2 Asian Subgroup Analysis

Cancer Research and Treatment (2020)

Subgroup analysis confirming palbociclib-letrozole efficacy and tolerability in East Asian HR+ MBC patients, supporting uniform international guidelines across populations.

🏆Awards & Recognition 奖项与荣誉

🏆Korean Cancer Society Distinguished Research Award
🏆Samsung Medical Center Academic Excellence Award
🏆Asia-Pacific Journal of Clinical Oncology Best Paper Award

📄Data Sources 数据来源

Last updated: 2026-01-15 | All information from publicly available academic sources

关注 林荣赫 的研究动态

Follow Young-Hyuck Im's research updates

留下邮箱,当我们发布与 Young-Hyuck Im(Samsung Medical Center, Sungkyunkwan University School of Medicine)相关的新研究或访谈时,我们会通知你。

我们不会泄露你的信息,也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment